一种新型的寡核酸端粒酶抑制剂Imetelstat的低预节律风险:一个翻译分析
Ashley L Lennox1, Libo Sun1, Fei Huang1
1Geron Corporation, Foster City, California, USA.
Clinical and translational science
|February 20, 2025
概括
一种新型端粒酶抑制剂Imetelstat在非临床和临床研究中没有显示出前节律失常的潜力. 在动物和患有骨髓分裂综合征的患者中进行的心血管评估证实了它在心脏再极化方面的安全性.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 心血管安全心血管安全
- 瘤学 药物开发 药物开发
背景情况:
- 伊梅特尔斯塔特是一种新型的寡核酸端粒酶抑制剂.
- 对前节律失常潜力的评估对于药物安全至关重要.
- 骨髓发育综合征 (MDS) 是一组癌症,其中不成熟的血细胞不能成熟或成为健康的血细胞.
研究的目的:
- 为了评估imetelstat.stat的前节律潜力.
- 评估imetelstat对心脏再极化 (QTc间隔) 的影响.
- 整合非临床和临床数据进行全面的风险评估.
主要方法:
- 在体外评估hERG通道电流抑制.
- 在Cynomolgus子体内进行心血管参数监测.
- 在IMerge III期试验中,对于较低风险的MDS患者进行了心室再极化副研究,包括密集的心电图和药物动力学分析.
主要成果:
- 在实验室中,Imetelstat没有抑制hERG通道.
- 在子中,没有观察到与治疗相关的心脏参数或QTc间隔 (QTcF) 的变化.
- 在MDS患者中,imetelstat在治疗剂量时对QTcF没有显著影响,预计Cmax变化为2.36毫秒.
结论:
- 非临床研究表明,在显著高于治疗水平的暴露时,没有预节律风险.
- 临床评估表明,imetelstat对QTc间隔或其他心电图参数没有临床显著的影响.
- 综合风险评估支持imetelstat.stat的低前节律潜力.
关键词:
这是一个ECGECGECGECGECG.在 QTC 间隔间隔.心血管疾病的风险.血液学 血液学 血液学在体外 (in vitro) 进行试验.在活体中,活体中这些都是新生儿瘤.患者患者患者患者患者患者患者第三阶段第三阶段在临床前的临床前.更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
相关概念视频
03:18Non-LTR Retrotransposons
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
02:15Replicative Cell Senescence
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...